NAD+ Precursor Chews vs. Fish Oil for Senior Dog Vitality: What the Bloodwork Actually Supports

By Koranda Walsh, VMD, DACVIM (SAIM), DACVP (CP)

✓ Medically reviewed by Koranda Walsh, VMD, DACVIM (SAIM), DACVP (CP) — August 6, 2026 For general education — not a substitute for veterinary care.

Value · August 9, 2026 · 6 min read

NAD+ precursor chews have one real dog trial behind them; fish oil has decades — that gap should shape your senior dog's supplement order.

The checklist before you buy either one

• Ask for the trial, not the theory. NAD+ precursor blends for dogs have exactly one published randomized controlled trial behind the combination product; fish oil has decades of veterinary trials on osteoarthritis and cognition.
• Read the dose, not the ingredient name. “Nicotinamide riboside” or “NMN” on a label tells you nothing about milligrams per pound — ask for the number.
• Check the fatty acid profile, not just “fish oil.” EPA and DHA content, not total fish oil weight, drives the anti-inflammatory effect.
• Run current bloodwork before adding either. Liver values and lipid panels change what I’d recommend for a given dog.
• Sequence, don’t stack blindly. If budget or pill burden is a constraint, I have owners choose one first and reassess in 8–12 weeks rather than layering both immediately.
• Ask what’s independently verified. NASC membership and a certificate of analysis matter more than a “senior vitality” claim on the front of the bag.

I’ll walk through why that order holds up, and where I’d actually deviate from it.

The limitation nobody puts on the NAD+ label

Here’s the thing about NAD+ precursor chews for dogs: the marketing outran the dog data by years. In humans, nicotinamide riboside has a real pharmacokinetic track record — a placebo-controlled trial in Nature Communications showed chronic NR supplementation was well tolerated and reliably raised blood NAD+ in middle-aged and older adults. That’s a solid mechanistic anchor. But raising a blood analyte in a person is not the same claim as improving vitality in a dog, and for years that was the entire evidence base owners were shown.

What changed the picture is a 2024 randomized controlled trial published in Scientific Reports, which tested a combined NAD+ precursor and senolytic compound in seventy senior dogs with mild to moderate cognitive impairment. Dogs on the full-dose combination showed a significantly larger drop in owner-assessed cognitive dysfunction rating scores than the placebo group. That’s a genuine, dog-specific, peer-reviewed result — and it’s also the only one of its kind. It tested one proprietary combination product, at specific doses, for cognitive scoring, not for joints, energy, or generalized “vitality.” When a chew’s label leans on NAD+ language without disclosing which compound, dose, or trial it’s actually built on, that’s the gap I’d want closed before recommending it.

What fish oil actually does to an inflamed joint

Fish oil’s evidence trail is longer and more specific. A randomized, double-blinded, controlled trial in the Journal of the American Veterinary Medical Association found that dogs with osteoarthritis supplemented with fish oil omega-3 fatty acids showed measurable improvement in weight-bearing, with the majority of treated dogs improving on force-plate measures compared to controls. That’s an objective, instrumented outcome — not just an owner questionnaire, though owner-reported outcomes matter too and are what most of us actually see in exam rooms.

The mechanism tracks with the outcome: EPA and DHA compete with arachidonic acid in the inflammatory cascade, which is the structural reason omega-3s show up consistently across osteoarthritis, skin, and cognitive-support literature in dogs. That consistency across independent trials, done by different research groups over more than a decade, is exactly the kind of convergent evidence a single 2024 trial hasn’t had time to build yet.

The 11-year-old spaniel that changed how I sequence this

I had a client bring in an 11-year-old, 34-pound cocker spaniel named Percy last winter. The owner’s complaint was specific: Percy used to meet her at the door every evening, and over about six weeks he’d started staying on his bed in the mudroom instead, only getting up when she called him twice. She’d also noticed he was slower going up the two steps to the kitchen and had started refusing his evening walk about half the time. She’d read about NAD+ chews online and wanted to start there because a friend’s dog was “doing great” on them. I asked for recent bloodwork first — her regular vet had run a senior panel four months earlier that was unremarkable except for a mildly elevated ALP, not unusual at that age. Given the joint-adjacent presentation (steps, activity refusal) alongside the behavioral change, we started fish oil at a therapeutic EPA/DHA dose and rechecked at eight weeks before considering anything else. That case is one dog, not a study, but it’s the kind of decision point I see repeated often enough that it shaped the sequence I now walk owners through by default.

Reading the label and the bloodwork before you combine them

This is where I foreground what I tell every owner in this exact position: a lab value only tells you something if you know what it’s ruling in or out. An ALP elevation alone doesn’t tell you a dog needs an NAD+ precursor or should avoid fish oil — but it does tell you to look closer before adding a supplement that adds hepatic or lipid load on top of an unclear picture. Fish oil dosed above the recommended range can worsen pancreatitis risk or prolong bleeding time in dogs on other medications, which is exactly why the dose on a bag matters more than the ingredient name. Owners who’ve read Signs Your Dog Needs a Probiotic: A Vet’s Whole-Patient Guide will recognize the same pattern: a single symptom rarely points to one clean answer, and the workup matters more than the supplement aisle.

I don’t reflexively recommend NAD+ chews against fish oil as a rule — that would be its own kind of hype. If a dog already has a well-managed joint protocol and the owner’s real concern is cognitive fog rather than mobility, the Scientific Reports trial is a legitimate reason to discuss a NAD+ precursor product, provided the label discloses its actual compound and dose. What I push back on is starting there by default because the branding sounds more cutting-edge than “fish oil,” when the joint and cognition evidence for omega-3s is deeper and the failure mode of getting the dose wrong is better understood.

A practical sequence for senior dogs

1. Pull or request a current geriatric bloodwork panel — CBC, chemistry, and a lipid check if fish oil is on the table.
2. Identify the primary complaint: joint stiffness and mobility point toward fish oil first; owner-reported cognitive slowing is where the NAD+ precursor trial is most directly relevant.
3. Confirm NASC membership or an equivalent third-party quality program on any product you’re considering, per the standards described by the National Animal Supplement Council.
4. Start one supplement, not both, and reassess at 8–12 weeks using the same specific markers the owner first noticed — stairs, greeting behavior, willingness to walk.
5. Only layer a second supplement once you’ve confirmed the first is tolerated and you can attribute any change to it specifically.

Where I land, and the honest counterargument

The strongest counterargument to leading with fish oil is that it’s “boring” — it’s been the default recommendation for a decade, and owners chasing a specific complaint like fading enthusiasm or slower cognition may not feel it’s addressing what they actually see. That’s fair, and it’s why the Scientific Reports cognitive trial deserves a real place in this conversation rather than being dismissed. But for the majority of senior dogs I see, the presenting complaint traces back to joint discomfort even when the owner describes it as general low energy — a dog that hurts to stand up will look “less vital” long before it looks lame. Fish oil’s decade-plus of convergent, mechanism-consistent evidence earns it the first slot in that sequence. NAD+ precursor chews earn a real, specific, and increasingly evidence-backed second slot — not a default one.

I keep coming back to one thing with owners like Percy’s: read the label and the bloodwork before the claim. That habit doesn’t change with the supplement category, and it’s the same habit I’d want every owner in a pet-supply aisle to walk in with, whether they’re looking at Does My Human Probiotic Capsule Contain Xylitol That’s Unsafe for My Dog? or a bag of chews promising cellular vitality.